Stopping antidepressants during pregnancy may lead to symptom recurrence

January 31, 2006

Women who stop taking antidepressant medications during pregnancy are at a five times greater risk for recurrence of depression than are women who continue taking their medication throughout their pregnancies, according to a multi-institutional study published in the February 1 Journal of the American Medical Association. The findings, from the first systematic clinical study of depression relapse during pregnancy, run counter to a common belief that pregnancy's hormonal changes can prevent psychiatric problems.

"Clinical lore has held for decades that pregnancy protected women from mood disorders," says Lee Cohen, MD, director of the Perinatal and Reproductive Clinical Research Program at Massachusetts General Hospital (MGH), who led the investigation. "What drove this study was a divergence between that belief and what many of us were seeing clinically, that many women who stopped using antidepressants during pregnancy appeared to be relapsing."

Many published studies have supported the safety of antidepressant drugs taken during pregnancy, although there have been some reports that prenatal exposure to the popular selective serotonin reuptake inhibitors (SSRIs) might cause transient agitation or distress in newborns. Most recently, some preliminary unpublished data suggested a potentially increased risk of cardiovascular defects in infants exposed to the SSRI paroxetine. The current study was designed to examine risk for recurrent depression in pregnant women who chose to continue or to stop antidepressants during pregnancy.

The study enrolled 201 women treated at women's mental health centers at MGH, University of California Los Angeles (UCLA) School of Medicine, and Emory University School of Medicine. All participants were less than 16 weeks pregnant when entering the study, had a history of depression and had been successfully treated with antidepressant medications for at least three months before they became pregnant.

The women were provided with audiotapes outlining what was known about the risk of birth defects associated with antidepressants and about the possible risk that their depression could recur if medication was discontinued. They then made their own decisions whether to maintain or discontinue antidepressant medication during pregnancy. A total of 82 chose to maintain their medication dosage; 65 discontinued antidepressants; 34 decreased dosage and 20 increased dosage during their pregnancies. Out of all participants, 43 percent experienced relapse of depression symptoms during pregnancy, half during the first trimester. But while 68 percent of those who discontinued medication relapsed, only 26 percent of those who maintained their prepregnancy dosage had recurrence of symptoms.

"We know that women who become depressed during pregnancy may not take appropriate care of themselves or even make it to prenatal appointments, and there is evidence that maternal depression itself has an adverse effect on fetal and neonatal well being," says Cohen. "While this report does not offer explicit guidelines for individual patients, the study unequivocally suggests that women taking antidepressants who anticipate pregnancy need to address with their doctors not only potential risks to their babies if they continue taking the drugs but also the risk that their disease may recur if they stop antidepressants. Only by considering both sides of this risk/benefit equation can patients make informed decisions."

Members of the research team are currently analyzing additional data from these study participants to look for characteristics that may indicate who could safely discontinue treatment and who would be at risk for recurrence. They also are planning to examine the factors women used as a basis for deciding whether to continue medication as well as other information that could be helpful to patients and physicians.
-end-
The group at Emory was led by Zachary Stowe, MD, and the UCLA team was led by Lori Altshuler, MD. Other coauthors of the JAMA study are Ruta Nonacs, MD, PhD, Adele Viguera, MD, and Alison Reminick of MGH; Rita Suri, MD, Vivien Burt, MD, PhD, and Victoria Hendrick, MD, of UCLA; Jeffrey Newport, MD, and Ada Loughead of Emory; and Bernard Harlow, PhD, and Allison Vitonis of Brigham and Women's Hospital. The study was supported by grants from the National Institute of Mental Health.

Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of nearly $500 million and major research centers in AIDS, cardiovascular research, cancer, cutaneous biology, medical imaging, neurodegenerative disorders, transplantation biology and photomedicine. In 1994, MGH and Brigham and Women's Hospital joined to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups, and nonacute and home health services.

Massachusetts General Hospital

Related Depression Articles from Brightsurf:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.

Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.

Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.

Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.

A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.

Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.

Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.

Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.

Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.

CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.

Read More: Depression News and Depression Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.